[{"orgOrder":0,"company":"Theratechnologies","sponsor":"Theratechnologies","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Theratechnologies","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Theratechnologies"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Doxorubicin peptide conjugate","moa":"Sortilin receptor 1","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"TH1902","moa":"Sortilin","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Docetaxel-TH19P01 conjugate","moa":"Sortilin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Theratechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Theratechnologies"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Docetaxel-TH19P01 conjugate","moa":"Sortilin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Italian Medicines Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Ibalisumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theratechnologies \/ Italian Medicines Agency","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Italian Medicines Agency"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibalisumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel-TH19P01 Conjugate","moa":"Sortilin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel-TH19P01 Conjugate","moa":"Sortilin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel-TH19P01 Conjugate","moa":"Sortilin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"TH1902","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Piramal","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Piramal"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Dermatology","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theratechnologies \/ Marathon Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Marathon Asset Management"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel-TH19P01 Conjugate","moa":"Sortilin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ PPD"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibalizumab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"TH1902","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibalizumab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"TH1902","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"TH1902","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"World Orphan Drug Alliance","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theratechnologies \/ World Orphan Drug Alliance","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ World Orphan Drug Alliance"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"TH1902","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Iibalizumab-uiyk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Sudocetaxel Zendusortide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Windtree Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Windtree Therapeutics"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Sudocetaxel Zendusortide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Sudocetaxel Zendusortide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Iibalizumab-uiyk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ibalizumab-uiyk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ibalizumab-uiyk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Iibalizumab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Sudocetaxel Zendusortide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Iibalizumab-uiyk","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Sudocetaxel Zendusortide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechnologies \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Theratechnologies
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
